promising Drug Combination Shows Early success in Combating Metabolic Dysfunction-Associated Steatohepatitis (MASLD)
Metabolic dysfunction-associated steatohepatitis (MASLD), formerly known as non-alcoholic steatohepatitis (NASH), is rapidly becoming a leading cause of liver disease globally, ofen linked to notable cardiovascular risk. A new study from the University of Barcelona (UB) offers a hopeful avenue for early intervention, demonstrating that a combination of two existing, well-established medications – pemafibrate and telmisartan - can effectively reverse fat accumulation in the liver, a hallmark of early-stage MASLD. This research, leveraging innovative modeling techniques, represents a significant step towards preventative treatment strategies for this increasingly prevalent condition.
The Challenge of Early MASLD Intervention
Traditionally, therapeutic development for liver diseases has focused on addressing advanced stages like cirrhosis. Though, a growing understanding of MASLD’s progression emphasizes the critical importance of intervention before irreversible damage occurs. As Dr. Marta alegret, lead researcher on the study, explains, “we have focused on these early phases wiht the aim of preventing the disease from progressing to more severe stages. But for a drug to be used in these early stages, it must have a good safety profile in humans.” This pragmatic approach led the team to investigate repurposing existing drugs with known safety records, potentially accelerating the path to clinical application.
Pemafibrate & Telmisartan: A Synergistic Approach
The study focused on pemafibrate, a lipid-lowering agent currently approved in Japan, and telmisartan, a widely prescribed antihypertensive medication. Both drugs are routinely used to mitigate cardiovascular risk, a crucial consideration given the high incidence of heart disease in MASLD patients. “Mortality from cardiovascular causes is significant in patients with MASLD, and often these patients also have these two risk factors together,” Dr.Alegret emphasizes.
The research revealed a compelling synergistic effect when the drugs were administered in combination. In both rat models and a novel zebrafish larval model – increasingly recognized for its ability to mimic mammalian carbohydrate and lipid metabolism – the combination reversed fat accumulation in the liver induced by a high-fat, high-fructose diet.Notably, using half the dose of each drug proved as effective as a full dose of either medication alone, suggesting a potential for reduced toxicity and improved patient tolerance.
“Combination therapy with drugs acting on different pathogenic pathways may be a better strategy than monotherapy, thanks to possible synergistic effects and reduced toxicity related to the use of lower doses of each drug,” Dr.Alegret notes. Beyond addressing liver fat, the combination offers a broader benefit by concurrently lowering blood pressure and cholesterol, further reducing cardiovascular risk.
Unlocking the Mechanism: The Role of PCK1
The study also shed light on the distinct mechanisms by which each drug exerts its protective effect. While telmisartan has previously been studied in later stages of MASLD, primarily for its anti-inflammatory and anti-fibrotic properties, this research reveals a previously unknown benefit in the early stages of the disease. Researchers discovered that telmisartan restores levels of the PCK1 protein in the livers of MASLD animals.
“This increase in PCK1 diverts the flux of metabolites from lipid synthesis to glucose synthesis,” explains the UB professor. Importantly,this shift in metabolic pathways did not lead to increased blood glucose levels,suggesting a safe and targeted effect. This revelation provides a crucial understanding of telmisartan’s early-stage efficacy and opens new avenues for targeted therapeutic development.
Zebrafish: A Powerful Tool for Liver Disease Research
The use of zebrafish larvae as a model organism is a key strength of this research. zebrafish offer several advantages over conventional animal models: they are simpler, cheaper, and allow for faster results. Their metabolic and physiological similarities to mammals make them a valuable tool for studying complex diseases like MASLD. “In recent years, zebrafish have emerged as an captivating option model that facilitates the study of the pathophysiology of MASLD and the evaluation of treatments,” says the UB professor.
looking Ahead: From Bench to Bedside
While these findings are highly encouraging, the researchers are quick to emphasize that clinical trials are essential to confirm the efficacy and safety of this drug combination in humans. “In order to be translated into a treatment for MASLD patients, clinical studies would be needed to show that the benefits observed in animal models also occur in humans,” Dr. alegret cautions.
The team is already planning further studies to investigate the effectiveness of the combination in more advanced stages of MASLD, including models of liver fibrosis. They are also developing a dual model incorporating both liver fibrosis and cardiovascular disease to assess the broader benefits of the treatment.
This research represents a significant advancement in the fight against MASLD, offering a promising, preventative strategy
